Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer.

We assayed the levels of soluble urokinase plasminogen activator receptor (su-PAR) with an ELISA in various body fluids from 77 patients with benign or malignant ovarian tumors, histologically classified as follows: benign; possibly malignant (borderline); and well, intermediately, and poorly differentiated malignant. The concentration of su-PAR in fluid from malignant cysts was extremely high, approximately 10-fold higher than the concentration in ascitic fluid and approximately 100-fold higher than that in blood. Also, the concentration in malignant cysts was approximately 10-fold higher than the concentration in benign cysts. Such high concentrations of su-PAR were found not only in truly malignant but also in possibly malignant cysts. Thus, we suggest that the concentration of su-PAR in cystic fluid can serve as a marker, allowing early diagnosis of malignant ovarian cysts. The concentration of su-PAR in fluid aspirated transvaginally with ultrasonographic guidance can be used to discriminate possibly and truly malignant cysts from benign cysts without surgery. The high concentrations of su-PAR in ovarian cystic fluids allowed us to characterize the molecular forms. Cross-linking of a radiolabeled ligand to the receptor demonstrated that at least a fraction of su-PAR was able to bind the ligand. A cleaved form of the receptor constituting domains 2 and 3 was detected with Western blotting. The cleaved receptor, which is devoid of the ligand-binding domain 1, has not previously been demonstrated in body fluids; it has only been demonstrated on cell surfaces. su-PAR domains 2 and 3 were found in cystic fluids from both malignant and benign ovarian tumors.

[1]  O. Wilhelm,et al.  128 A cellular GPI-specific phospholipase D regulates the biological function of the urokinase receptor , 1997 .

[2]  H. Nielsen,et al.  ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. , 1997, Clinical chemistry.

[3]  M. Duffy,et al.  The urokinase‐type plasminogen activator system in cancer metastasis: A review , 1997, International journal of cancer.

[4]  M. Ploug,et al.  Cell-surface acceleration of urokinase-catalyzed receptor cleavage. , 1997, European journal of biochemistry.

[5]  Michael V. Doyle,et al.  Regulation of Integrin Function by the Urokinase Receptor , 1996, Science.

[6]  K. Preissner,et al.  The urokinase receptor is a major vitronectin-binding protein on endothelial cells. , 1996, Experimental cell research.

[7]  S. Rosenberg,et al.  Identification of the urokinase receptor as an adhesion receptor for vitronectin. , 1994, The Journal of biological chemistry.

[8]  K. Danø,et al.  Urokinase and urokinase receptor expression in somatic cell hybrids , 1994 .

[9]  N. Brünner,et al.  A cleaved form of the receptor for urokinase‐type plasminogen activator in invasive transplanted human and murine tumors , 1994, International journal of cancer.

[10]  N. Brünner,et al.  Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. , 1994, Cancer research.

[11]  C. Cohen,et al.  Screening for ovarian cancer: the role of noninvasive imaging techniques. , 1994, American journal of obstetrics and gynecology.

[12]  F. Jänicke,et al.  A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. , 1993, The Journal of clinical investigation.

[13]  J. Soria,et al.  The plasminogen‐activation system in ovarian tumors , 1993, International journal of cancer.

[14]  N. Brünner,et al.  Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. , 1993, Cancer research.

[15]  L. Lund,et al.  Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. , 1992, The Journal of biological chemistry.

[16]  I. Mizukami,et al.  cDNA for Mo3, a monocyte activation antigen, encodes the human receptor for urokinase plasminogen activator. , 1992, Journal of immunology.

[17]  B. Gustavsson,et al.  Cell membrane receptors for urokinase plasminogen activator are increased in malignant ovarian tumours. , 1991, European journal of cancer.

[18]  M. Ploug,et al.  Cell‐induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2‐terminal domain of the urokinase receptor , 1991, FEBS letters.

[19]  M. Ploug,et al.  Protein Structure and Membrane Anchorage of the Cellular Receptor for Urokinase-Type Plasminogen Activator , 1991, Seminars in thrombosis and hemostasis.

[20]  F. Blasi,et al.  Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. , 1991, The American journal of pathology.

[21]  F. Blasi,et al.  The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator. , 1991, The Journal of biological chemistry.

[22]  R. Bast,et al.  The CA 125 tumour-associated antigen: a review of the literature. , 1989, Human reproduction.

[23]  A. Corti,et al.  Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[24]  D. Belin,et al.  A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase , 1985, The Journal of cell biology.

[25]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.